|
|
Stakeholder Opinions: Skin Infections - Where In The Antibacterial Lifecycle?Published by: Datamonitor Published: Jun. 17, 2004 - 137 Pages Table of ContentsTABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 3 Scope of the analysis 3 Datamonitor insight into the community-acquired RTI market 4 While skin infections represent one of the most common types of bacterial infection, prescriptions associated with these conditions only account for a relatively limited percentage of total community antibacterial sales (e.g. 3% of US drugstore sales in 2003 attributable to skin infections.) Companies developing and marketing broad-spectrum antibacterials should consider skin infections as a secondary target, focusing resources on higher value indications, such as respiratory tract infections. 4 High unmet need in the management of skin infections involving resistant pathogens increases the likelihood of gaining fast-track designation in the US, as demonstrated by Cubist’s Cubicin (daptomycin) and Basilea’s novel cephalosporin, BAL5788. The potential for rapid market entry, reduced development costs and focused physician targets presents an attractive proposition for smaller players with limited resources. 5 While the management of acne generates almost $200m per year in antibacterial sales, differences in physician involvement in the management of this condition, relative to other bacterial infections, limit the potential of indication expansion into this area. Across the seven major markets, the majority of acne patients are treated by dermatologists (73% of acne antibacterial sales - IMS Health, Prescribing Insights, April 2004), whereas other bacterial infections are managed predominantly by GPs, family practitioners and pediatricians. Companies should consider the clear lack of synergy between acne and other bacterial infections when evaluating product development and life-cycle management options. 7 Summary 9 Key metrics 10 CHAPTER 2 DISEASE DEFINITION AND EPIDEMIOLOGY 19 Disease definition 19 Furunculosis 20 Definition 20 Symptoms 20 Risk factors and associated conditions 20 Folliculitis 21 Definition 21 Symptoms 21 Risk factors 22 Impetigo 23 Definition 23 Symptoms 23 Risk factors and associated conditions 23 Staphylococcal scalded skin syndrome 23 Definition 23 Symptoms 24 Risk factors 24 Cellulitis 24 Definition 24 Symptoms 24 Risk Factors 25 Etiology 27 Erysipelas 27 Necrotising fasciitis 28 Definition 28 Symptoms 28 Etiology 29 Myositis 29 Definition 29 Symptoms 29 Risk factors 30 Acne 30 Definition 30 Symptoms 30 Risk factors 31 Staphylococcus aureus - the most common cause 31 Staphylococcus aureus toxins 31 Staphylococcus aureus resistance in skin infections 31 CHAPTER 3 PRESENTATION, DIAGNOSIS AND TREATMENT 34 Presentation 34 Initial presentation and care 34 Referral patterns 35 Case study: United Kingdom 36 NHS care 36 Private care 37 Hospital vs. community management 37 Reasons for hospital admission 38 Diagnosis 39 CHAPTER 4 MARKET ANALYSIS BY DRUG CLASS 40 Market definition 40 Diagnoses included in the analysis 40 The importance of skin infections 41 Penicillins 44 Contribution of SSTIs to penicillin use 47 Macrolides 48 Contribution of SSTIs to macrolide use 51 Cephalosporins 53 Contribution of SSTIs to cephalosporin use 55 Fluoroquinolones 56 Contribution of SSTIs to fluoroquinolone use 59 Zyvox 60 Contribution of SSTIs to Zyvox use 60 Key SSTI indications treated with Zyvox 61 CHAPTER 5 MARKET ANALYSIS BY INDICATION 64 Impetigo 64 Therapeutic choice 64 Treating physicians 66 Analyst comment 68 Cellulitis 68 Therapeutic choice 69 Treating physicians 72 Analyst comment 73 Acne 74 Therapeutic choice 76 Treating physicians 77 Analyst comment 80 CHAPTER 6 STRATEGIC ANALYSIS 82 Community prescriptions - hard to influence? 82 Large target audience? 82 Geographical dispersion of target audience 83 Increasing involvement and variability of stakeholders 84 Increasing competition necessitates greater differentiation 85 SSTIs - line-extension or quick route in? 85 Indication expansion 85 Skin infections - route of entry for smaller players? 87 APPENDIX A 89 Supporting data 89 Opinion leader transcripts 90 List of tables 123 List of figures 123 Bibliography 125 Bibliography 125 Report methodology 129 APPENDIX B 130 About Datamonitor 130 About Datamonitor Healthcare 130 Datamonitor Healthcare’s research and analysis methodologies 131 Datamonitor Healthcare’s therapy area capabilities 131 About the infectious disease analysis team 132 Datamonitor Healthcare’s Consulting expertise 133 Datamonitor’s Therapeutic Consulting expertise 133 Key therapy team members 134 John Savopoulos, Lead analyst, Infectious Diseases 134 David Abramson, Therapeutic Lead Consultant 135 Disclaimer 136 AbstractIntroductionBacterial skin and skin structure infections are among the most common infections treated within the community setting. There are a wide range of different types of infection, each with individual symptoms, epidemiology and etiology. However, the majority require antibacterial treatment and, as a result, represent potential lucrative targets for novel product development and indication expansion. Scope Disease definitions, symptoms, epidemiology and risk factors for key skin and skin structure infections Detailed seven country market analysis by class and indication, including volume and value assessments Breakdown of prescriptions for key skin infections by physician type, across the seven major markets Strategic analysis and recommendations for maximizing the potential of the skin infections sector Highlights Prescriptions associated with skin infections account for only a small percentage of total community antibacterial sales (e.g. 3% of US drugstore sales). Companies developing and marketing broad-spectrum antibacterials should consider skin infections as a secondary target, focusing primary resources on higher value indications. High unmet need in the management of skin infections involving resistant pathogens increases the likelihood of gaining fast-track designation in the US. The potential for rapid market entry, reduced development costs and focused physician targets presents an attractive proposition for smaller players with limited resources. There is a clear lack of synergy between acne and other bacterial infections, in terms of prescribing physicians and focus classes. Companies involved in antibacterial product development or life-cycle management should bear this in mind when considering indication expansions. Reasons to Purchase Effectively prioritize skin infections within your antibacterial portfolio with detailed prescription and sales data Target detailing campaigns more effectively with in-depth understanding of physicians involved in the management of skin infections Identify key strategies to maximize the potential of bacterial skin infections for both key players and new market entrants Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||